Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Abcam Licenses Novel Technology from Columbia University for Neurobiological Research

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
New products from Abcam Biochemicals will support research into neurodegeneration and drug addiction.

Abcam Plc. and Columbia University, announced that they have entered into an exclusive license agreement for two novel pH-responsive fluorescent false neurotransmitters (FFNs). FFNs are probes which act as optical tracers, allowing imaging of neurotransmitter release from individual presynaptic terminals in the brain. Under the terms of the agreement, Abcam Biochemicals will provide the FFN compounds to its customers as part of the Abcam Biochemicals range, to support both fundamental and applied neurobiological research, including neurodegeneration and drug addiction.

The two FFNs licenced by Abcam are FFN102 and FFN202, which are first-of-a-kind small molecules that act as pH sensors. FFN102, which allows measurement of activity at dopamine synapses, enables the further study of synaptic plasticity by allowing optical imaging of dopaminergic presynaptic terminals. FFN202 may be used to screen drugs and other molecules to examine their effects on the pH of secretory vesicles.

Both FFN102 and FFN202 are sufficiently bright, photostable and suitable for two-photon and standard fluorescence microscopy and are compatible with GFP tags.

Steve Roome, general manager of Abcam Biochemicals explains “This is now our third collaboration with Columbia University, and we are delighted to be working with them again. Entering into such a license agreement will allow us to offer the ground-breaking FFN102 (Mini102) and FFN202 (Mini202) compounds to researchers, and both are now available as part of the Abcam Biochemicals range.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abcam Acquires AxioMx
AxioMx provides a unique, cost-effective, and proprietary platform to produce recombinant monoclonal antibodies complementing Abcam's existing innovative production capabilities.
Friday, November 13, 2015
Abcam Acquires Firefly BioWorks
Acquisition will expand Abcam’s capabilities in multiplex analysis.
Wednesday, January 21, 2015
Abcam Partners with A*STAR’s Institute of Molecular and Cell Biology
Abcam Partners with A*STAR’s Institute of Molecular and Cell Biology.
Thursday, January 08, 2015
Abcam plc Announces Board Appointment
Appointment of Sue Harris as a non-Executive Director on the Company’s Board.
Saturday, December 13, 2014
Abcam Appoints Yvonne Chien as Chief Digital Officer
Abcam’s leadership team strengthened by new appointments.
Saturday, December 13, 2014
Abcam Wins ‘Best Use of Digital Media’ at Life Science Industry Awards
Awards recognise the world’s top performing life science suppliers.
Wednesday, November 19, 2014
Abcam Licenses Multidrug Resistance Protein 4 Inhibitors
Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development.
Tuesday, September 23, 2014
Abcam and Cell Marque Sign Global Strategic Marketing Agreement
Partnership extends Abcam’s reach within in vitro diagnostics market.
Saturday, September 06, 2014
Abcam Establishes New Direct Service for Australia and New Zealand
New service will offer researchers improved delivery times and direct technical support.
Tuesday, August 12, 2014
Abcam Announces Winner of 15 Discoveries Contest
Contest celebrates scientific breakthroughs with $15,000 research grant.
Tuesday, February 04, 2014
Abcam to Open Office in Shanghai
New office will provide dedicated support to Chinese customers.
Tuesday, January 21, 2014
Abcam Named AIM Company of the Year
The AIM awards celebrate outstanding achievement of quoted companies and entrepreneurs who have harnessed AIM to help them fulfil their ambition and growth potential in the last twelve months.
Monday, October 14, 2013
Abcam Appoints Alan Hirzel as Chief Marketing Officer
New role will support future growth strategies at Abcam.
Friday, June 28, 2013
Abcam Signs License Agreement with Pfizer
Company to supply a range of authentic Pfizer compounds to researchers.
Wednesday, June 12, 2013
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Automated Patch Clamping Trends
Learn more about current practices, preferences and metrics in ion channel drug screening using APC technology.
Lab-on-a-Stick: Miniaturised Clinical Testing For Fast Detection Of Antibiotic Resistance
A portable power-free test for the rapid detection of bacterial resistance to antibiotics has been developed by academics at Loughborough University and the University of Reading.
Genetic Ancestry of Cultivated Strawberry Unravelled
UNH scientists constructed a linkage map of the seven chromosomes of the diploid Fragaria iinumae, which allows them to fill in a piece of the genetic puzzle about the eight sets of chromosomes of the cultivated strawberry.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
New Drug Target for Inflammatory Disorders
Penn study finds enigmatic molecules maintain equilibrium between fighting infection and inflammatory havoc.
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Mechanisms of Calcium Blockers
Researchers describe how the fundamental mode of action of two distinct chemical classes of calcium channel blockers differs.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!